Breaking News

Almac Article Details Breast Cancer Assay

By Kristin Brooks | January 22, 2014

Predictive gene aims to identify potential chemotherapy response

The article entitled “Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer” led by Almac’s medical director, professor Richard Kennedy, was recently published in the Journal of the National Cancer Institute (JNCI). The article details the development and initial validation of a predictive gene signature for chemotherapy response in breast cancer.
 
Almac’s objective in the development of the assay was to provide a means of identifying breast cancer patients more likely to respond to standard of care chemotherapy treatment. The assay was developed by Almac in collaboration with Queens University, Belfast and the Mayo Clinic, Rochester, U.S. Almac provided microarray analysis of patient samples and identified a molecular subgroup with a deficiency in DNA damage repair, termed DDRD for DNA Damage Repair Deficient. Almac then developed a 44 gene classifier capable of identifying this molecular group in patient tumor samples. The test has been developed and validated using formalin fixed paraffin embedded (FFPE) tissue using Almac’s Breast Cancer DSA.
 
“The publication of this data represents a significant milestone for Almac as we transition this assay into the clinic. The publication of these results combined with our recent out-licensing of the assay to Genomic Health for use in breast cancer patients, highlights the quality of the science being carried out here in Almac,” said professor Paul Harkin, president and managing director of Almac’s Diagnostics business unit.
 

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks